Helius Medical Technologies, Inc. (HSDT)
| Market Cap | 24.72M |
| Revenue (ttm) | 623,000 |
| Net Income (ttm) | -16.93M |
| Shares Out | 1.29M |
| EPS (ttm) | -16.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $16.90 |
| Previous Close | $16.56 |
| Change ($) | 0.34 |
| Change (%) | 2.05% |
| Day's Open | 16.77 |
| Day's Range | 16.10 - 17.00 |
| Day's Volume | 38,481 |
| 52-Week Range | 11.23 - 1,788.50 |
NEWTOWN, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, tod...
The Company's Stock Will Continue to be Listed and Traded on The Nasdaq Stock Market
NEWTOWN, Pa., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, tod...
Submits formal response to the U.S. Food and Drug Administration's request for additional information Submits formal response to the U.S. Food and Drug Administration's request for additional ...
NEWTOWN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, is ...
NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, tod...
NEWTOWN, Pa., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, ann...
Helius Medical Technologies' (HSDT) Management on Q3 2020 Results - Earnings Call Transcript
NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, tod...
New clinics increase access to PoNS Treatment in population-dense areas across Canada New clinics increase access to PoNS Treatment in population-dense areas across Canada
NEWTOWN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, tod...
NEWTOWN, Pa., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, ann...
NEWTOWN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, ann...
NEWTOWN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, tod...
NEWTOWN, Pa., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, t...
Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies
NEWTOWN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, ...
NEWTOWN, Pa., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, t...
NEWTOWN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, t...
Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q2 2020 Results - Earnings Call Transcript
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 33.33% and 33.00%, respectively, for the quarter ended June 2020.
NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, t...
NEWTOWN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, t...
Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
NEWTOWN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, t...
NEWTOWN, Pa., July 14, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), announced the dismissal of a putative shareholder class...
NEWTOWN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, to...
Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q1 2020 Results - Earnings Call Transcript
122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment™ Provides Significant Improvement in Balance and Gait Deficits for Individuals Who Have Experienced a Mi...
122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment™ found Significant Improvement in Balance and Gait Deficits for Individuals Who Have Experienced a Mild-...
NEWTOWN, Pa., April 22, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness...
NEWTOWN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), today announced that its Canadian Class II license ame...
NEWTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, ...
Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q4 2019 Results - Earnings Call Transcript
Expands Access to PoNS Treatment™ in the Greater Toronto Area and Southwestern Ontario Expands Access to PoNS Treatment™ in the Greater Toronto Area and Southwestern Ontario
NEWTOWN, Pa., March 02, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, ...
NEWTOWN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”) CEO Philippe Deschamps has been invited to brief the US ...
The Cline Medical Centre in Nanaimo is the Eighth Authorized PoNS Treatment™ Clinic in Canada.
Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of Biopharma
NEWTOWN, Pa., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), would like to clarify that the agreement between the co...
NEWTOWN, Pa., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, a...
Brain Mapping Foundation and Society for Brain Mapping Therapeutics name the Portable Neuromodulation Stimulator ( PoNS™) device a trailblazing technology Brain Mapping Foundation and Society ...
NEWTOWN, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (the “Company”), a neurotech company focused on neurological wellness, announced tod...
NEWTOWN, Pa., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, a...
NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, a...
NEWTOWN, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, t...
Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q3 2019 Results - Earnings Call Transcript
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 0.00% and -50.00%, respectively, for the quarter ended September 2019.
NEWTOWN, Pa., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, t...
Demand for traumatic brain injury management brings revolutionary neurological health technologies to Canada’s capital Demand for traumatic brain injury management brings revolutionary neurolo...
About HSDT
Helius Medical Technologies, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator (PoNS), a medical device in Canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function. The company is headquartered in Newtown, Pennsylvania.
| Industry Medical Devices | |
| CEO Philippe Deschamps | Employees 19 |
| Stock Exchange NASDAQ | Ticker Symbol HSDT |
Financial Performance
In 2019, HSDT's revenue was $1.50 million, an increase of 212.97% compared to the previous year's $478,000. Losses were -$9.78 million, -65.83% less than in 2018.